NRG Oncology

Quick facts

Phase 3 pipeline

• Adjuvant Chemotherapy + Ovarian Function Suppression · Oncology
  This combination treatment uses chemotherapy drugs to kill cancer cells while simultaneously suppressing ovarian function to reduce estrogen production and protect fertility in premenopausal women with breast cancer.
• Gonadotrophin Releasing Hormone · Oncology
  Gonadotropin-releasing hormone (GnRH) agonists stimulate the pituitary gland to release luteinizing hormone and follicle-stimulating hormone, which initially increases sex hormone production before causing downregulation and suppression of testosterone and estrogen.
• Ovarian Function Suppression + Aromatase Inhibitor · Oncology
  This combination suppresses ovarian estrogen production while blocking the conversion of androgens to estrogen, reducing total circulating estrogen in premenopausal women with hormone receptor-positive breast cancer.

Phase 2 pipeline

• CAPOX 3 month · Oncology
  Capecitabine is a thymidylate synthase inhibitor.
• CAPOX 6 month · Oncology
  Capecitabine is a thymidylate synthase inhibitor.
• Imaging Agent
• mFOLFOX6 3-6 month
• mFOLFOX6 6 month
• MnSOD Mimetic BMX-001

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• NRG Oncology portfolio CI brief
• NRG Oncology pipeline updates RSS